论文部分内容阅读
目的 从细胞水平探讨乳腺癌耐药机制 ,以期为选择化疗方案提供参考 ,获得更有效的化疗效果。方法 应用免疫组化S -P法 ,对乳腺癌的主要耐药指标GST -π、TOPOⅡ进行检测 ,并结合临床分期进行研究。结果 (1)乳腺癌中GST -π表达率为 6 3.6 % (2 8/4 4) ,临床Ⅲ期表达率显著高于临床Ⅰ、Ⅱ期。 (2 )TOPOⅡ表达率为 47.7% (2 1/4 4) ,临床Ⅲ期表达率显著低于Ⅰ、Ⅱ期。 (3)TOPOⅡ与GST -π表达关系间无明显相关性 ,说明它们各自的表达从不同方面对肿瘤耐药起作用。结论 在乳腺癌化疗药物选择时 ,联合检测GST -π、TOPOⅡ的表达具有指导作用 ,对预后的判断有参考价值。
Objective To explore the mechanism of breast cancer resistance at the cellular level in order to provide a reference for the selection of chemotherapy regimens and to obtain more effective chemotherapy effects. Methods Immunohistochemical S-P method was used to detect GST-π and TOPOII, the major drug resistance indicators in breast cancer, and the clinical stage was studied. Results (1) The expression rate of GST-π in breast cancer was 63.6% (28/44). The clinical stage III expression rate was significantly higher than that of clinical stages I and II. (2) The expression rate of TOPOII was 47.7% (2 1/4 4). The clinical stage III expression rate was significantly lower than that of stage I and II. (3) There was no significant correlation between the expression of TOPOII and GST-π, indicating that their respective expressions played a role in tumor resistance from different aspects. Conclusion In the selection of chemotherapy drugs for breast cancer, the combined detection of GST-π, TOPO II expression has a guiding role in the prognosis of the judgement of reference value.